ALSO NOTED: Takeda to collaborate with Santhera; Isotechnika touts trial results; Orchid Chemicals raising $100M; and much more

> Japan's Takeda has bought into Santhera's experimental treatment for Friedreich's Ataxia. Story

> Isotechnika is touting interim results for their Phase III trial of its lead immunosuppressive drug. Release

> India's Orchid Chemicals plans to raise $100 million to pay down debt and fund new development. Story

> Regulators have cited Merck for violating FDA rules when it changed a manufacturing process for a leukemia drug without testing to see if it was effective. Story

> Cobra Biomanufacturing and Auxilium Pharmaceuticals have extended their agreement for the production and supply of the protein biopharmaceutical AA4500. Release

> Cytochroma has announced positive results for a Phase Ib trial of its experimental psoriasis treatment. Release

And Finally... New "smart" bio-nanotubes may help improve drug delivery techniques. Release

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.